Veterinary Clinical Reference
Look up any drug or condition.
Evergreen, evidence-based hubs on the drugs, conditions, and species you manage — continuously updated and cited at every claim.
Canine Hypoadrenocorticism: Diagnostic Testing
Use resting cortisol to exclude disease, ACTH stimulation to confirm deficiency, and endogenous ACTH to classify canine hypoadrenocorticism.
Read →Canine Eclampsia: Calcium Treatment and Monitoring
A clinician-focused approach to puerperal hypocalcemia: calcium interpretation, monitored stabilization, diagnostic alternatives, and a coordinated dam-and-litter plan.
Read →Feline Mammary Fibroadenomatous Hyperplasia: Workup
A history-led workup for rapid mammary enlargement: identify hormonal exposure, assess pregnancy, recognize sampling limitations, and escalate unresolved masses.
Read →Canine Pseudopregnancy: Mammary Swelling Diagnostic Workup
A problem-oriented workup for lactation and mammary enlargement: exclude pregnancy and uterine disease, sample inflammation, and investigate focal masses.
Read →Methimazole and Carbimazole for Feline Hyperthyroidism: Pharmacology, Dosing, and Adverse Effect Management
Methimazole 1.25-2.5 mg PO BID is the standard medical therapy for feline hyperthyroidism, controlling but not curing disease. This hub consolidates dosing, adverse-effect management, carbimazole and transdermal options, and how medical management compares with radioiodine, iodine-restricted diet, and surgery — including the concurrent-CKD reversibility trial.
Read →Velagliflozin (Senvelgo) for Feline Diabetes Mellitus: SGLT2 Inhibition, Efficacy and Safety
Velagliflozin (Senvelgo) is a once-daily oral SGLT2 inhibitor for the insulin-naive diabetic cat: the SENSATION trial (n=252) cut median blood glucose from 436 to 125 mg/dL by day 180. This hub covers efficacy, the euglycemic DKA hazard, mandatory BHB monitoring, patient selection, and how it compares with bexagliflozin and insulin.
Read →Trilostane (Vetoryl) for Canine Hyperadrenocorticism: Evidence and Monitoring
Trilostane (Vetoryl) inhibits 3β-HSD for canine hyperadrenocorticism, resolving PU/PD in 70% and skin changes in 62% of dogs. Emerging evidence favours pre-trilostane cortisol over the ACTH stimulation test for monitoring clinical control.
Read →